Literature DB >> 9317153

Human tryptase fibrinogenolysis is optimal at acidic pH and generates anticoagulant fragments in the presence of the anti-tryptase monoclonal antibody B12.

S Ren1, A E Lawson, M Carr, C M Baumgarten, L B Schwartz.   

Abstract

Human tryptase is uniquely regulated by its association with heparin and resists inhibition by biological protease inhibitors. The effects of pH and B12, an IgG anti-tryptase mAb, on cleavage of the synthetic substrate tosyl-Gly-Pro-Lys-p-nitroanilide and of the biological substrate fibrinogen by tryptase were examined. Tosyl-Gly-Pro-Lys-pnitroanilide cleavage was optimal at neutral pH and was inhibited by the B12 mAb at acidic and neutral pH values. At pH 7.5, inhibition was reversible and noncompetitive. In contrast, the optimal pH for tryptase to cleave fibrinogen was acidic. B12 dramatically enhanced the rate and extent that tryptase cleaved all three fibrinogen subunits at pH 6.0 to 6.5, but inhibited these activities at neutral pH. Major fibrinogen cleavage fragments generated at acidic pH by the B12:tryptase complex were identical with those made by plasmin. Thus, at acid pH, tryptase alone destroyed the ability of fibrinogen to clot, while the B12:tryptase complex increased the rate of fibrinogenolysis and also generated the anticoagulant, fragment D. The acidic pH optimum for tryptase fibrinogenolysis may direct this activity to tissue sites of inflammation. A putative biological equivalent to B12 would limit tryptase fibrinogenolytic activity at sites of neutral pH, such as blood, but would augment activity at acidic sites.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9317153

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized beta-tryptase to form monomers that are inactive at neutral pH and active at acidic pH.

Authors:  Yoshihiro Fukuoka; Lawrence B Schwartz
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

Review 2.  Mast cell tryptases and chymases in inflammation and host defense.

Authors:  George H Caughey
Journal:  Immunol Rev       Date:  2007-06       Impact factor: 12.988

3.  Allosteric control of βII-tryptase by a redox active disulfide bond.

Authors:  Kristina M Cook; H Patrick McNeil; Philip J Hogg
Journal:  J Biol Chem       Date:  2013-10-18       Impact factor: 5.157

Review 4.  Regulation and function of mast cell proteases in inflammation.

Authors:  C Huang; A Sali; R L Stevens
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

5.  Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5.

Authors:  Yoshihiro Fukuoka; Han-Zhang Xia; Laura B Sanchez-Muñoz; Anthony L Dellinger; Luis Escribano; Lawrence B Schwartz
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

Review 6.  Active monomers of human beta-tryptase have expanded substrate specificities.

Authors:  Yoshihiro Fukuoka; Lawrence B Schwartz
Journal:  Int Immunopharmacol       Date:  2007-07-27       Impact factor: 4.932

7.  A novel serine protease predominately expressed in macrophages.

Authors:  Cailin Chen; Andrew L Darrow; Jian-Shen Qi; Michael R D'Andrea; Patricia Andrade-Gordon
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

8.  VEGF is involved in the increase of dermal microvascular permeability induced by tryptase.

Authors:  Qianming Bai; Xiaobo Li; Xinhong Wang; Yali Xu; Li Wang; Qingyong Zhang; Lianhua Yin
Journal:  ISRN Dermatol       Date:  2012-05-15

9.  A French National Survey on Clotting Disorders in Mastocytosis.

Authors:  Ana B Carvalhosa; Achille Aouba; Gandhi Damaj; Danielle Canioni; Chantal Brouzes; Emmanuel Gyan; Stéphane Durupt; Isabelle Durieu; Pascal Cathebras; Nathalie Costédoat-Chalumeau; David Launay; Benoit Pilmis; Stephane Barete; Laurent Frenzel; Olivier Lortholary; Olivier Hermine; Cedric Hermans; Marie-Olivia Chandesris
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.